FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

A / a a la i a a 4 a a	D C	20540
Vashington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Ezekowitz Alan</u>					Ful	2. Issuer Name and Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [FULC] 3. Date of Earliest Transaction (Month/Day/Year)							eck all appli X Directo	r	erson(s) to Iss 10% Ow Other (s	ner
(Last)	(F	irst)	(Middle)			06/27/2023								Officer (give title below)		pecily
C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street) CAMBR	IDGE M	ÍΑ	02139		Du		10h5-	1/c) Transa	ction Inc	dication		Form f Persor	iled by More th	an One Repo	rting
(City)	(S	,	(Zip)			Chec satisf	k this box y the affirr	to inc	licate that a trai e defense condi	nsaction was tions of Rule	made pursu 10b5-1(c). S	ant to a con ee Instruction	on 10.	on or written plar	n that is intende	ed to
		Tab	le I - Nor	n-Deriv	ative	Sec	curities	S Ac	quired, Di	.			ly Owned	<u> </u>		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execution Date,			Code (Instr. 5)			Benefici	es Formally (D) (Following (I) (I	m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	/ Amoun	t (A) or Price		Transac (Instr. 3	tion(s)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$3.16	06/27/2023			A		30,000		(1)	06/26/2033	Common Stock	30,000	\$0.00	30,000	D	

Explanation of Responses:

1. This option was granted on June 27, 2023 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.

> /s/ Greg Tourangeau, as attorney-in-fact for Alan

06/29/2023

Ezekowitz

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.